DVA at a glance
DaVita (DVA, SEC CIK 927066) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), DaVita (DVA) reported revenue of $13.6 billion (up 6.5% from FY2024) and net income of $746.8 million. Diluted EPS was $9.84.
- As of September 30, 2026, 36 institutional investment managers tracked by SignalX reported holding DaVita (DVA) shares worth $7.8 billion in 13F-HR filings.
- In the last 90 days, DVA insiders reported 0 open-market purchases ($0) and 1 open-market sale ($69.0M) on Form 4, a net sale of $69.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $13.6B
- +6.5% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$69.0M
- 13F holders
- 36 funds
- $7.8B · −1 vs prior quarter
- Latest 8-K
- Oct 29, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Providing kidney care services with significant revenues from commercial insurance and government programs like Medicare, Medicaid, and Veterans Affairs
- New emphasis: Expansion in integrated kidney care offerings including home-based dialysis, U.S. integrated kidney care business, and ancillary services
- Strategic shift: Increased focus on negotiating private payor contracts amid downward reimbursement pressures and evolving value-based care models
- Quantitative metric: Approximately 200,500 U.S. dialysis patients managed, with commercial payors generating nearly all profit from dialysis treatment
- Noteworthy risk: Severe 2024 supply chain disruption from a natural disaster caused increased expenses and slowed growth in home dialysis business
Risk Factors
- Legal risk: accrual for potential third-party judgment costs of $25 million for unspecified legal matters
- Macroeconomic exposure: $10.16 billion long-term debt principal maturity with $5.29 billion due after 2030
- Operational risk: revenue estimating risk up to 1% of revenue, impacting ~5% of U.S. dialysis operating income due to complex payor billing
- Competitive risk: goodwill impairment triggered by changes in reimbursement structure or market conditions affecting segments
- Financial risk: $1.53 billion potential cash obligations from put provisions for noncontrolling interests in dialysis partnerships
Management Discussion & Analysis
- Forward-looking risks include reimbursement rate declines, patient mix shifts, and increased competition pressures
- Cybersecurity incident in 2025 noted, impacting billing systems and cash flow variability risks
- Capital allocation plans discussed in general terms; no specific buyback, dividend, or capex amounts provided
- Management highlights regulatory, market, supply chain, labor, and technology risks affecting future operations and growth
AI summary of the DVA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Nine-month revenue $10.548B, up 5.2% YoY from $10.023B
- U.S. dialysis revenue $9.004B, up 3.3% YoY, strongest segment
- Operating income $1.560B, up 5.2% YoY from $1.483B, operating margin figures not provided
- Operating cash flow $1.330B vs $1.346B YoY, share repurchases $870M for 5.837M shares
- Headwinds: commercial mix pressure, rising labor and supply costs, policy uncertainty, China impairment charges of $62M
Risk Factors
- No material changes to risk factors disclosed in the 2025 10-K
- Carried-forward risk: forward-looking statements in quarterly Management’s Discussion and Analysis
- Carried-forward risk: risks detailed in the 2025 10-K remain applicable
AI summary of the DVA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 revenue $3.578B, operating income $499M, adjusted EPS $3.82, with adjusted operating margin 15.7%
- Adjusted 2026 operating-income guidance raised to $2.175B-$2.250B from prior low of $2.150B
Item 2.02: Results of Operations and Financial Condition
- DaVita announced financial results for the quarter ended September 30, 2026
- Full revenue, earnings and operating details are in Exhibit 99.1, the attached earnings release
Item EX-99.1: Item EX-99.1
- Q2 revenue $3.554B and operating income $579M, with operating margin expanding to 16.3% from 14.1% in Q1
- Diluted EPS $4.02 versus $2.87 in Q1, supported by net income attributable to DaVita Inc. of $265M
Item 2.02: Results of Operations and Financial Condition
- DaVita announced financial results for the quarter ended June 30, 2026
- Detailed operating metrics and financial figures are in Exhibit 99.1, the accompanying earnings release
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 disclosure is incomplete, providing no amount, terms, interest rate, maturity, or borrowing purpose
- Investors should review the filing’s exhibits for the underlying financial obligation details
Item 1.01: Entry into a Material Definitive Agreement
- $500M incremental borrowing under senior secured Tranche B-2 term facility maturing May 2031
- Interest: Term SOFR plus 175 basis points or Base Rate plus 75 basis points
Item 5.07: Submission of Matters to a Vote of Security Holders
- 59,865,902 shares represented, approximately 91% of outstanding shares, indicating strong shareholder participation
- All nine director nominees elected for terms expiring at the 2027 annual meeting
AI summaries of DVA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DVA
Don't miss the next DVA filing
- Alerts as it files. A push when DVA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DVA, by share count.
- Ask anything. An AI agent that reads every DVA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Schoppert Wendy Lee | A | Nov 15, 2026 | 286 | - |
| Moore Gregory J. | A | Nov 15, 2026 | 286 | - |
| Schechter Adam H | A | Nov 15, 2026 | 286 | - |
| DESOER BARBARA J | A | Nov 15, 2026 | 286 | - |
| Arway Pamela M | A | Nov 15, 2026 | 286 | - |
| Hollar Jason M. | A | Nov 15, 2026 | 286 | - |
| BERRY CHRISTOPHER MICHAEL | F | Nov 15, 2026 | 1,031 | $174.56 |
| Rodriguez Javier | F | Nov 15, 2026 | 5,165 | $174.56 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $12.8B | $13.6B |
| Operating Income | - | $2.1B | $2.0B |
| Net Income | $691.5M | $936.3M | $746.8M |
| Op. Margin | - | 16.3% | 15.0% |
| Net Margin | - | 7.3% | 5.5% |
| Balance Sheet | |||
| Total Assets | $16.9B | $17.3B | $17.5B |
| Equity | - | $121.1M | -$651.1M |
| ROE | - | 773.1% | -114.7% |
| Per Share | |||
| EPS | $7.42 | $10.73 | $9.84 |
| Cash Flow | |||
| Operating CF | - | $2.0B | $1.9B |
| CapEx | $568.0M | $555.4M | $575.9M |
Source: XBRL data in DaVita (DVA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate DVA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 36 | $7.82B |
| Q2 2026 | 37 | $9.85B |
| Q1 2026 | 36 | $7.11B |
| Q4 2025 | 34 | $5.55B |
| Q3 2025 | 33 | $6.65B |
| Q2 2025 | 32 | $7.50B |
| Q1 2025 | 30 | $7.60B |
| Q4 2024 | 28 | $7.33B |
- AQR Capital Management+556.1K (+95%)
- BlackRock+272.9K (+11%)
- Citigroup+235.2K (+822%)
- Invesco Ltd+213.8K (+18%)
- Vanguard Portfolio Management LLC+195.9K (+14%)
- Bank of America Corp−278.8K (-43%)
- D.E. Shaw & Co−271.8K (-42%)
- BNY Mellon−219.5K (-48%)
- Berkshire Hathaway Inc−183.0K (-1%)
- Citadel Advisors LLC−151.7K (-76%)
- FMR LLC (Fidelity)−114.5K
- Two Sigma Investments−20.2K
- Renaissance Technologies LLC−6.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 266 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DVA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Oct 29, 2026 | - | - | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
Related Health Care companies
- AGL · agilon health, inc.Services-Misc Health & Allied Services, NEC
- PGNY · Progyny, Inc.Services-Misc Health & Allied Services, NEC
- VMD · VIEMED HEALTHCARE, INC.Services-Misc Health & Allied Services, NEC
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
DVA SEC filings: frequently asked questions
Are DVA insiders buying or selling?
In the last 90 days, DaVita (DVA) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $69.0 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold DVA stock?
As of September 30, 2026, the largest DaVita (DVA) holders among the 13F filers tracked by SignalX were Berkshire Hathaway Inc ($5.0 billion), BlackRock ($478.2 million), Vanguard Capital Management LLC ($395.2 million), Morgan Stanley ($287.2 million), Vanguard Portfolio Management LLC ($275.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was DVA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), DaVita (DVA) reported revenue of $13.6 billion (up 6.5% from FY2024) and net income of $746.8 million. Diluted EPS was $9.84. The figures come from the XBRL data in the 10-K.
What are the main risks in DVA's latest 10-K?
In the 10-K filed February 11, 2026, DaVita (DVA) flagged: Legal risk: accrual for potential third-party judgment costs of $25 million for unspecified legal matters. Macroeconomic exposure: $10.16 billion long-term debt principal maturity with $5.29 billion due after 2030. (AI summary of the Risk Factors section.)
What did DVA report in its latest 8-K?
DaVita (DVA) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $3.578B, operating income $499M, adjusted EPS $3.82, with adjusted operating margin 15.7%.
What are the latest DVA SEC filings?
DaVita (DVA) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 17, 2026.
What is DVA's SEC CIK number?
DaVita (DVA)'s SEC Central Index Key (CIK) is 927066. EDGAR lists every DVA filing under that number.
Ask anything about DVA
The research agent reads DVA's filings, financials, insider trades and 13F holders, then answers with sources.